Consonance Capital Management LP Argenx Se Transaction History
Consonance Capital Management LP
- $7.28 Million
- Q3 2022
Shares
2 transactions
Others Institutions Holding ARGX
# of Institutions
400Shares Held
32.2MCall Options Held
361KPut Options Held
399K-
Price T Rowe Associates Inc Baltimore, MD5.6MShares$3.36 Billion0.29% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.51MShares$2.11 Billion2.99% of portfolio
-
Janus Henderson Group PLC London, X02.47MShares$1.48 Billion0.58% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD1.92MShares$1.15 Billion0.52% of portfolio
-
Capital World Investors Los Angeles, CA1.7MShares$1.02 Billion0.15% of portfolio
About ARGENX SE
- Ticker ARGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,323,800
- Market Cap $33.2B
- Description
- argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...